Vivoryon Therapeutics N.V.: Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
DGAP-News: Vivoryon Therapeutics N.V.
/ Key word(s): AGM/EGM
Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.
HALLE (SAALE) / MUNICH, GERMANY, 12 March 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) announced today that its shareholders approved all resolutions proposed by the Company's Board of Directors at the Company's Extraordinary General Meeting (EGM) which took place on Friday, March 12, 2021, as a virtual event, including the:
1. Reappointment of Dr. Ulrich Dauer as executive member of the Board.
The Board nominated Dr. Ulrich Dauer for reappointment as executive member of the Board and regranted him the title of Chief Executive Officer, effective May 1st, 2021.
2. Appointment of Mr. Florian Schmid as executive member of the Board.
The Board nominated Mr. Florian Schmid for appointment as executive member of the Board and granted him the title of Chief Financial Officer, effective April 1st, 2021.
3. Appointment of KPMG Accountants N.V., Amsterdam, The Netherlands, as external auditor for the financial year 2020.
20.06% of the voting shares were represented at the 2021 Vivoryon Therapeutics N.V. EGM.
All resolutions proposed by the Company's Board of Directors were approved at the meeting with a large majority. The voting results can be found on the Company's website:
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
12.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||Vivoryon Therapeutics N.V.|
|Phone:||+49 (0)345 555 9900|
|Fax:||+49 (0)345 555 9901|
|Listed:||Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam|
|EQS News ID:||1175352|
|End of News||DGAP News Service|